Amundi Reduces Position in ICU Medical, Inc. $ICUI

Key Points

• Amundi has reduced its stake in ICU Medical, Inc. by 19.6%, taking its total holdings to 10,240 shares worth approximately $1,450,000.
• CEO Vivek Jain purchased 21,929 shares of ICU Medical at an average cost of $112.84 per share, enhancing his position by 20.26%.
• Analysts have upgraded ICU Medical to a "buy" rating, with a consensus price target of $181.00 and diverse investment opinions, reflecting a potential for growth despite recent stock fluctuations.

Amundi decreased its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 19.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,240 shares of the medical instruments supplier's stock after selling 2,496 shares during the period. Amundi's holdings in ICU Medical were worth $1,450,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in ICU Medical by 27.2% during the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock valued at $99,000 after purchasing an additional 153 shares during the period. SG Americas Securities LLC bought a new position in ICU Medical during the first quarter valued at approximately $859,000. Vontobel Holding Ltd. bought a new position in ICU Medical during the first quarter valued at approximately $235,000. EP Wealth Advisors LLC bought a new position in ICU Medical during the first quarter valued at approximately $479,000. Finally, Envestnet Asset Management Inc. lifted its position in ICU Medical by 8.2% during the first quarter. Envestnet Asset Management Inc. now owns 20,269 shares of the medical instruments supplier's stock valued at $2,815,000 after purchasing an additional 1,534 shares during the period. Institutional investors own 96.10% of the company's stock.

Insider Buying and Selling at ICU Medical

In related news, Director David C. Greenberg bought 1,200 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The stock was bought at an average cost of $126.42 per share, with a total value of $151,704.00. Following the completion of the purchase, the director owned 7,960 shares of the company's stock, valued at approximately $1,006,303.20. The trade was a 17.75% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Vivek Jain bought 21,929 shares of the business's stock in a transaction that occurred on Thursday, August 14th. The shares were bought at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the purchase, the chief executive officer directly owned 130,149 shares of the company's stock, valued at $14,686,013.16. This represents a 20.26% increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

ICUI has been the topic of a number of research analyst reports. Piper Sandler increased their price objective on shares of ICU Medical from $145.00 to $153.00 and gave the company an "overweight" rating in a research report on Wednesday, September 10th. Wall Street Zen upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a research report on Friday, September 5th. Finally, Raymond James Financial decreased their price target on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, ICU Medical has a consensus rating of "Buy" and an average target price of $181.00.

ICU Medical Price Performance

Shares of ICUI stock traded up $3.92 on Thursday, hitting $133.02. 350,997 shares of the stock traded hands, compared to its average volume of 258,987. The firm has a market cap of $3.28 billion, a price-to-earnings ratio of -87.51 and a beta of 0.86. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $196.26. The firm has a 50 day simple moving average of $126.01 and a two-hundred day simple moving average of $133.39. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, beating the consensus estimate of $1.44 by $0.66. The firm had revenue of $543.57 million for the quarter, compared to the consensus estimate of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company's revenue was down 8.0% on a year-over-year basis. During the same period last year, the firm earned $1.56 EPS. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, equities research analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.